Inactive Instrument

Other languages Eleven Biotherapeutics Inc Nasdaq

Equities

US2862211065

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline	Apr. 01
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01
Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors	Apr. 01
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment	Dec. 14
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy	Nov. 28
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	Nov. 28
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Carisma Therapeutics Inc. Presents Pre-Clinical Proof of Concept for in vivo CAR-M Using mRNA Platform in Collaboration with Moderna at SITC	23-10-31
Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023	23-10-25
Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit	23-09-01
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors	23-06-28
Carisma Therapeutics Inc. Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources	23-06-14
Carisma Therapeutics Inc. Provides Pipeline Updates	23-05-12
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Carisma Therapeutics Files for Potential Follow-on, Secondary Offerings	23-04-18
CARISMA Therapeutics Inc. completed the acquisition of Sesen Bio, Inc. from The Vanguard Group, Inc., JEC II Associates, LLC, BML Investment Partners, L.P. managed by BML Capital Management, LLC and others in a reverse merger transaction.	23-03-06
Sesen Bio Gets Shareholders Nod for Carisma Therapeutics Merger, to Pay Special Dividend	23-03-02
Sesen Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Sesen Bio, Inc. Announces Increase of One-Time Special Cash Dividend	23-02-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Eleven Biotherapeutics Inc Nasdaq

Equities

US2862211065

Other languages

Filters